NCT04436276View on ClinicalTrials.gov

A Study of Ad26.COV2.S in Adults (COVID-19)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

1,085

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

February 21, 2023

Study Completion Date

February 21, 2023

Conditions
Covid-19 Prevention
Interventions
BIOLOGICAL

Ad26.COV2.S

Participants will receive intramuscular (IM) injection of Ad26.COV2.S.

BIOLOGICAL

Placebo

Participants will receive Placebo.

Trial Locations (12)

2170

Clinical Pharmacology Unit, Merksem

2650

Universiteit Antwerpen - Centrum voor de Evaluatie van Vaccinaties (CEV), Edegem

UZA-SGS, Edegem

3000

UZ Leuven, Leuven

9000

Center for Vaccinology (CEVAC), Ghent

20850

Optimal Research, Rockville

32934

Optimal Research, Melbourne

37923

AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville

61614

Optimal Research, Peoria

78744

Optimal Research, Austin

92108

Optimal Research, San Diego

02215

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT04436276 - A Study of Ad26.COV2.S in Adults (COVID-19) | Biotech Hunter | Biotech Hunter